{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/it-time-go-beyond-classic-design-oncology-trials#webpage",
"url": "https://www.fortrea.com/insights/it-time-go-beyond-classic-design-oncology-trials",
"name": "Is it time to go beyond classic design in oncology trials?",
"description": "Explore this Fortrea white paper on innovative oncology trial design and discover how modern clinical development approaches are helping sponsors move beyond traditional oncology study models to improve flexibility, efficiency, and overall trial execution. The white paper examines adaptive oncology clinical trials, innovative study methodologies, biomarker-driven development strategies, and operational approaches that support more effective oncology drug development. Learn how adaptive trial methodologies, targeted oncology therapy strategies, streamlined operations, and data-driven clinical planning are helping accelerate oncology development, improve study efficiency, optimize patient selection, and support more agile execution of complex oncology clinical trials."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Is it time to go beyond classic design in oncology trials?",
"item": "https://www.fortrea.com/insights/it-time-go-beyond-classic-design-oncology-trials"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/it-time-go-beyond-classic-design-oncology-trials#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/it-time-go-beyond-classic-design-oncology-trials#webpage"
},
"headline": "Innovative Oncology Trial Design & Clinical Development Strategies | Fortrea White Paper",
"description": "Explore this Fortrea white paper on innovative oncology trial design and discover how modern clinical development approaches are helping sponsors move beyond traditional oncology study models to improve flexibility, efficiency, and overall trial execution. The white paper examines adaptive oncology clinical trials, innovative study methodologies, biomarker-driven development strategies, and operational approaches that support more effective oncology drug development. Learn how adaptive trial methodologies, targeted oncology therapy strategies, streamlined operations, and data-driven clinical planning are helping accelerate oncology development, improve study efficiency, optimize patient selection, and support more agile execution of complex oncology clinical trials.",
"genre": "White Paper",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-03/go-beyond-classic-design-in-oncology-trials.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-03-17",
"dateModified": "2025-03-17",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-03/go-beyond-classic-design-in-oncology-trials.pdf",
"encodingFormat": "application/pdf"
}
}
]
}